FDA Expands Approval of Omnipod 5 Insulin Delivery System to Include Patients With Type 2 Diabetes

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

TUESDAY, Aug. 27, 2024 -- On Monday, the U.S. Food and Drug Administration approved the Insulet Omnipod 5 insulin delivery system for patients with type 2 diabetes. It is the first such system for use by people with the more prevalent form of the disease.

The FDA first signed off on the system, which automatically adjusts insulin delivery as needed, for type 1 diabetes in 2022. In approving Insulet's Omnipod 5 insulin delivery system for type 2 diabetes patients, the FDA said the clearance "provides a new option that can automate many of these manual tasks [of tracking and managing blood glucose levels], potentially reducing the burden of living with this chronic disease."

"The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management," Michelle Tarver, M.D., acting director of the FDA Center for Devices and Radiological Health, said in a news release announcing the expanded use. "The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes."

Insulet applauded the expanded approval.

"Today's announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes," Insulet CEO Jim Hollingshead said in a company news release.

With the new system, the wearable product provides up to three days of nonstop insulin delivery without the need to handle a needle. The Omnipod 5 works in concert with a continuous glucose monitor to manage blood glucose with no daily injections and no finger pricks.

In approving the expanded use, the FDA reviewed data from a clinical study of 289 individuals 18 years and older with type 2 diabetes for 13 weeks. Volunteers' blood glucose control improved, and these improvements were seen across all demographic groups. Adverse events were generally mild to moderate and included hyperglycemia, hypoglycemia, and skin irritation.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords